Use Incremental 510(k)s To Bring Combo Products To Market, Attorney Says
This article was originally published in The Gray Sheet
Executive SummaryPursuing a series of 510(k)s instead of a PMA for a combination product may save a manufacturer millions of dollars and many years in getting to market, Kathleen Knight, an attorney with the Fort Worth, Texas, law firm Whitaker, Chalk, Swindle & Sawyer says
You may also be interested in...
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.